Dr. Shawn Yazdani is one of the area’s most
renowned interventional cardiologists, known for his specialization in structural
heart care and innovative approach to interventional cardiology.
He was the first operator in Northern Virginia to switch to the radial access uniformly in his practice, a method now adopted by most operators in the area.
He then became a
cofounder of Carient Heart and Vascular.
Starting the first Chronic Total Occlusion (CTO) program during his time at INOVA, he has today performed the greatest number of successful procedures in the area.
Leading the way for new interventional
techniques, Dr. Yazdani has performed more CTO procedures than any other
interventional cardiologist in the area, applying new techniques to
successfully open these types of arteries unresponsive to
conventional interventional techniques and relieve once life-limiting symptoms
for patients across Virginia.
over two decades of experience treating complex coronary lesions utilizing
atherectomy, thrombectomy, hemodynamic support and other results-driven,
evidence based techniques with a focus on patient outcome.
Dr. Yazdani became interested in treating
structural heart disease in 2012 when science supported the use of transcatheter aortic valve replacement (TAVR) techniques, in lieu of open heart surgery, to treat aortic valve
disease, specifically aortic stenosis.
He was involved in the initial trials
observing transcatheter therapy in patients at high or prohibitive risk for
surgical valve replacement. Since then, he has served as primary investigator in
many other trials, including Partner 3, Early TAVR, and Galileo. He has been
the lead physician in bringing non-surgical alternative access, such as
Transcaval valve replacement, to Northern Virginia - for patients who do not
have good femoral access for valve delivery.
Dr. Yazdani has performed more TAVR
procedures in Northern Virginia than any other operator.
He remains involved in research and continues to pioneer nonsurgical catheter based treatments.
a few physicians were performing this procedure nationwide, he has since broadened it popularly and become instrumental in bringing to the area different mitral valve treatment modalities,
such as Lampoon (laceration of the anterior leaflet of the mitral valve prior
to transcatheter replacement of the mitral valve), to the area.
He is the primary investigator for the
Apollo trials, involving transcatheter replacement of the mitral valve, or
transcatheter mitral valve replacement (TMVR), in patients at high or
intermediate risk for surgical valve replacement. He is also known for his
expertise in mitral valve repair therapies such as MitraClip.
Dr. Yazdani is also involved in therapies
geared towards patients with atrial fibrillation (AFib) and at high risk for taking
blood thinners such as Coumadin.
He regularly performs implantation of Left Atrial
Appendage (LAA) Occluders such as the WATCHMAN™ device.
Despite having a busy interventional
practice, he also holds regular office hours in multiple locations in Northern
Virginia including Vienna, Manassas and Warrenton.
Dr. Yazdani completed both his
undergraduate degree in Biology and his medical degree at New York University.
His postgraduate training included a residency in internal medicine, followed
by a Cardiology residency at Columbia Presbyterian Hospital. He then finished
his interventional training at Mount Sinai Hospital.
Fellow, American College of Cardiology (FACC)
Fellow, Society of Coronary Angiography and Intervention (FSCAI)
Carient Heart & Vascular Office Locations
415 Church Street NE, 101
Vienna, VA 22180
8100 Ashton Avenue, Suite 200
Manassas, VA 20109
559 Frost Avenue, Suite 102
Warrenton, VA 20186